InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.715 -0.015 (-2.05%)+
Announcement
Release
26 Aug 2026 9:45AM
Price at Release
$0.730
Full Release
download
Summary
Starpharma Holdings Limited, an innovative biotechnology company specializing in dendrimer technology, reported significant financial and operational achievements for the fiscal year ending 30 June 2026. The company ended FY26 with a cash balance of $11.0 million, which was subsequently strengthened by raising $30 million through an Entitlement Offer. Starpharma reported a 145% increase in revenue, amounting to $12.0 million, primarily driven by an upfront payment from the Genentech license agreement. The reported loss improved to $7.5 million, down 25% from the previous year, as the company continued investing in its DEP® pipeline. Key advancements include the progress of the DEP® HER2-Lutetium radiopharmaceutical asset and the expansion of its strategic partnerships. With a focus on targeted oncology treatments, Starpharma aims to enhance shareholder value and patient outcomes through its DEP® technology.
Key Points
  • Ended FY26 with cash balance of $11.0 million; raised $30 million after year-end.
  • FY26 revenue increased by 145% to $12.0 million.
  • Reported loss improved by 25% to $7.5 million.
  • Continued investment in DEP® pipeline and radiopharmaceutical assets.
  • Strengthened strategic partnerships and focused on targeted oncology treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.